Persistent lipid abnormalities in patients with hypertension and dyslipidemia treated with statins: results of the Portuguese hypertensive subpopulation of the Dyslipidemia International Study (DYSIS)

Abstract

This study aimed to assess the treatment patterns and prevalence of persistent lipid abnormalities in Portuguese hypertensive patients concomitantly treated with statins. Only 25% of the 656 hypertensive patients achieved the blood pressure goals in use during the study period. Similarly, only 33% and 37% attained the recommended levels of total cholesterol <4.5 mmol/L and LDL cholesterol <2.5 mmol/L, respectively. Relatively low doses of medium potency statins were the mainstay of therapy. There seems to be considerable room for improvement through the use of more potent statins, dose up-titration, and/or addition of other lipid-modifying therapies.

• Cardiovascular disease
• dyslipidemia
• HMG-CoA
• hypertension
• simvastatin
• statins

Declaration of interest

A. M. F. served as a part-time consultant for MSD Portugal, a subsidiary of Merck & Co., Inc. The authors report no other conflicts of interest in this work.